Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 250

1.

Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease.

Shah AA, Rosen A, Hummers LK, May BJ, Kaushiva A, Roden RBS, Armstrong DK, Wigley FM, Casciola-Rosen L, Visvanathan K.

Clin Exp Rheumatol. 2017 Jun 19. [Epub ahead of print]

PMID:
28628466
2.

Fibrosing myopathy in systemic sclerosis associates with higher mortality.

Paik JJ, Wigley FM, Shah AA, Corse AM, Casciola-Rosen L, Hummers LK, Mammen AL.

Arthritis Care Res (Hoboken). 2017 May 23. doi: 10.1002/acr.23291. [Epub ahead of print]

PMID:
28544788
3.

Reply.

Shah AA, Rosen A, Hummers LK, Wigley FM, Xu G, Elledge SJ, Casciola-Rosen L.

Arthritis Rheumatol. 2017 Apr 28. doi: 10.1002/art.40132. [Epub ahead of print] No abstract available.

PMID:
28454209
4.

Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study.

Kwakkenbos L, Thombs BD, Khanna D, Carrier ME, Baron M, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mayes MD, Mouthon L, Nielson WR, Poiraudeau S, Riggs R, Sauvé M, Wigley F, Hudson M, Bartlett SJ; SPIN Investigators.

Rheumatology (Oxford). 2017 Apr 18. doi: 10.1093/rheumatology/kex055. [Epub ahead of print]

PMID:
28431140
5.

The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Bello RJ, Cooney CM, Melamed E, Follmar K, Yenokyan G, Leatherman G, Shah AA, Wigley FM, Hummers LK, Lifchez SD.

Arthritis Rheumatol. 2017 Apr 20. doi: 10.1002/art.40123. [Epub ahead of print]

PMID:
28426903
6.

Brief Report: Anti-RNPC-3 Antibodies As a Marker of Cancer-Associated Scleroderma.

Shah AA, Xu G, Rosen A, Hummers LK, Wigley FM, Elledge SJ, Casciola-Rosen L.

Arthritis Rheumatol. 2017 Jun;69(6):1306-1312. doi: 10.1002/art.40065.

PMID:
28217959
7.

Exhaled nitric oxide in pulmonary arterial hypertension associated with systemic sclerosis.

Cao Z, Mathai SC, Hummers LK, Shah AA, Wigley FM, Lechtzin N, Hassoun PM, Girgis RE.

Pulm Circ. 2016 Dec;6(4):545-550. doi: 10.1086/688768.

8.

Update of EULAR recommendations for the treatment of systemic sclerosis.

Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, Del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, Müller-Ladner U; EUSTAR Coauthors.

Ann Rheum Dis. 2017 Aug;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909. Epub 2016 Nov 9.

PMID:
27941129
9.

Independent Association of Severity of Muscle Weakness With Disability as Measured by the Health Assessment Questionnaire Disability Index in Scleroderma.

Paik JJ, Wigley FM, Mejia AF, Hummers LK.

Arthritis Care Res (Hoboken). 2016 Nov;68(11):1695-1703. doi: 10.1002/acr.22870. Epub 2016 Oct 9.

PMID:
26881982
10.

Raynaud's Phenomenon.

Wigley FM, Flavahan NA.

N Engl J Med. 2016 Aug 11;375(6):556-65. doi: 10.1056/NEJMra1507638. Review. No abstract available.

PMID:
27509103
11.

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GH, Tseng CH, Elashoff RM; Sclerodema Lung Study II Investigators.

Lancet Respir Med. 2016 Sep;4(9):708-19. doi: 10.1016/S2213-2600(16)30152-7. Epub 2016 Jul 25.

PMID:
27469583
12.

Risk of Digital Vascular Events in Scleroderma Patients Who Have Both Anticentromere and Anti-Interferon-Inducible Protein 16 Antibodies.

McMahan ZH, Wigley FM, Casciola-Rosen L.

Arthritis Care Res (Hoboken). 2017 Jun;69(6):922-926. doi: 10.1002/acr.22978.

PMID:
27389713
13.

Unique Abnormalities in Right Ventricular Longitudinal Strain in Systemic Sclerosis Patients.

Mukherjee M, Chung SE, Ton VK, Tedford RJ, Hummers LK, Wigley FM, Abraham TP, Shah AA.

Circ Cardiovasc Imaging. 2016 Jun;9(6). pii: e003792. doi: 10.1161/CIRCIMAGING.115.003792. Epub 2016 Jun 7.

14.

Right Ventricular Functional Reserve in Pulmonary Arterial Hypertension.

Hsu S, Houston BA, Tampakakis E, Bacher AC, Rhodes PS, Mathai SC, Damico RL, Kolb TM, Hummers LK, Shah AA, McMahan Z, Corona-Villalobos CP, Zimmerman SL, Wigley FM, Hassoun PM, Kass DA, Tedford RJ.

Circulation. 2016 Jun 14;133(24):2413-22. doi: 10.1161/CIRCULATIONAHA.116.022082. Epub 2016 May 11.

15.

Enrichment of Scleroderma Vascular Disease-Associated Autoantigens in Endothelial Lineage Cells.

McMahan ZH, Cottrell TR, Wigley FM, Antiochos B, Zambidis ET, Park TS, Halushka MK, Gutierrez-Alamillo L, Cimbro R, Rosen A, Casciola-Rosen L.

Arthritis Rheumatol. 2016 Oct;68(10):2540-9. doi: 10.1002/art.39743.

PMID:
27159521
16.

Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma.

Fava A, Cimbro R, Wigley FM, Liu QR, Rosen A, Boin F.

Arthritis Res Ther. 2016 May 4;18(1):99. doi: 10.1186/s13075-016-0993-2.

17.

Thrombotic complications after radial arterial line placement in systemic sclerosis: A case series.

Paik JJ, Hirpara R, Heller JA, Hummers LK, Wigley FM, Shah AA.

Semin Arthritis Rheum. 2016 Oct;46(2):196-9. doi: 10.1016/j.semarthrit.2016.03.015. Epub 2016 Mar 31.

PMID:
27139167
18.

Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients.

Wu M, Assassi S, Salazar GA, Pedroza C, Gorlova OY, Chen WV, Charles J, Taing ML, Liao K, Wigley FM, Hummers LK, Shah AA, Hinchcliff M, Khanna D, Schiopu E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Zhou X, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Fritzler MJ, Molitor JA, Segal BM, Movahedian M, Martín J, Varga J, Mayes MD.

Arthritis Res Ther. 2016 Jan 20;18:20. doi: 10.1186/s13075-016-0923-3.

19.

Anti-Interferon-Inducible Protein 16 Antibodies Associate With Digital Gangrene in Patients With Scleroderma.

McMahan ZH, Shah AA, Vaidya D, Wigley FM, Rosen A, Casciola-Rosen L.

Arthritis Rheumatol. 2016 May;68(5):1262-71. doi: 10.1002/art.39558.

20.

Development and Validation of the Body Concealment Scale for Scleroderma.

Jewett LR, Malcarne VL, Kwakkenbos L, Harcourt D, Rumsey N, Körner A, Steele RJ, Hudson M, Baron M, Haythornthwaite JA, Heinberg L, Wigley FM, Thombs BD; Canadian Scleroderma Research Group.

Arthritis Care Res (Hoboken). 2016 Aug;68(8):1158-65. doi: 10.1002/acr.22819.

PMID:
26663624

Supplemental Content

Loading ...
Support Center